Cited by Factors influencing Nirmatrelvir/Ritonavir concentration in patients with COVID-19

Real-world Plasma Exposure of Nirmatrelvir/Ritonavir in Chinese Hospitalized Patients With COVID-19: A Multicenter Retrospective Study DOI

Zhiyuan Ma,

Mengru Bai,

Shuying Shen

et al.

Therapeutic Drug Monitoring, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 30, 2025

Nirmatrelvir/ritonavir is licensed for the treatment of mild-to-moderate coronavirus disease (COVID-19) in patients at an increased risk progression to severe disease. However, data on real-world plasma exposure nirmatrelvir/ritonavir remain limited, particularly Chinese patients. This study aimed assess trough concentration (Ctrough) and identify its critical factors hospitalized treated with 300 mg/100 mg twice daily over a 5-day course. A high-performance liquid chromatography-tandem mass spectrometry assay was developed validated measure Ctrough. Correlation analyses were performed variables influencing Among 110 patients, 100% had concentrations above antiviral vitro 90% effective concentration. The median Ctrough nirmatrelvir 4.55 mcg/mL (15.6× concentration), ranging from 0.65 12.44 mcg/mL. Nirmatrelvir normal mild renal impairment cohorts comparable (4.09 ± 1.97 4.57 2.21 mcg/mL) but significantly moderate cohort (6.41 2.31 mcg/mL). Sex, age, obesity not associated exposure. high COVID-19, therapeutic drug monitoring should be routinely recommended, except impairment.

Language: Английский

Citations

Population Pharmacokinetics of Nirmatrelvir in Chinese Patients with COVID-19: Therapeutic Drug Monitoring and Dosing Regimen Selection in Clinical Practice DOI

Ping Yang, Wei Liu, Yingqiu Ying

et al.

International Journal of Antimicrobial Agents, Journal Year: 2024, Volume and Issue: 64(2), P. 107199 - 107199

Published: May 24, 2024

Language: Английский

Citations

Model-informed drug development in pediatric, pregnancy and geriatric drug development: States of the art and future DOI

Yue-E Wu,

Yuanyuan Zheng,

Qiu‐Yue Li

et al.

Advanced Drug Delivery Reviews, Journal Year: 2024, Volume and Issue: 211, P. 115364 - 115364

Published: June 25, 2024

Language: Английский

Citations

An insight into pharmacokinetics and dose optimization of antimicrobials agents in elderly patients DOI

Guanshuang Fu,

Weijia Sun,

Zhaoyi Tan

et al.

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: Sept. 30, 2024

The global elderly population is on the rise, and infections tend to have a higher mortality rate among older individuals. Aging associated with progressive impairment of multi-organ function, which can impact pharmacokinetics antimicrobials, potentially leading failure anti-infective therapy. With increasing life expectancy, significant growth in demographic, escalating costs healthcare, gaining thorough understanding pharmacokinetic changes holds crucial clinical significance. This review compiles findings from published studies, offering comprehensive overview various antimicrobials both adults elderly. Furthermore, it delves into advancements methods specific population.

Language: Английский

Citations

Target Attainment and Population Pharmacokinetics of Nirmatrelvir/Ritonavir in Critically Ill Adult Patients DOI

Na Chen,

Xu‐Ben Yu, Lu Li

et al.

Infection and Drug Resistance, Journal Year: 2024, Volume and Issue: Volume 17, P. 4055 - 4065

Published: Sept. 1, 2024

The population pharmacokinetics of nirmatrelvir/ritonavir (NIR/RIT) has not yet been described for critically ill adult patient.

Language: Английский

Citations

Population pharmacokinetics of nirmatrelvir/ritonavir in critically ill Chinese COVID-19 patients and recommendations for medication use: a two-center retrospective study DOI

Junjun Xu, Jinmeng Li, Meng Chen

et al.

Expert Review of Clinical Pharmacology, Journal Year: 2024, Volume and Issue: 17(11), P. 1071 - 1079

Published: Sept. 26, 2024

This study aimed to establish population pharmacokinetics (PPK) models of nirmatrelvir/ritonavir in critically ill Chinese patients with the coronavirus disease 2019 (COVID-19) infection, explore factors affecting (PK) nirmatrelvir/ritonavir.

Language: Английский

Citations

Therapeutic Drug Monitoring of Nirmatrelvir/Ritonavirin Patients with COVID-19 DOI

xu ping,

Lijun Zhang,

wu qingguo

et al.

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 19, 2024

Abstract Background The aim of this study is to retrospectively analyze the factors that lead drug concentration Nirmatrelvir/Ritonavir (NMV/RTV) not reaching standard. Methods In study, NMV/RTV concentration(Cnmv/rtv)data (n = 114) COVID-19 patients over 18 years old were collected from May 2022 October 2022, and results compared. According analysis early NMV/RTV, combined with research at home abroad, according whether measured > 987ng/ml, divided into target group non-target ,The was defined as trough level. Results Serum in adult correlated prognostic nutritional index [PNI,(P < 0.05)], height (P 0.05), weight 0.05) creatinine clearance [Crcl ,(P 0.05)]. Multivariate showed height, weight, PNI, lymphocyte (LYM) CrCl independent influencing concentration. However, after correction BMI calculation, there no correlation between BMI, so clinical medication plan, adjusted weight. Conclusions serum gradually decreased increase CrCl. For high low CrCl, should be continuously monitored dosing regimen achieve these reduce effect PNI also a key factor affecting poor status, closely dose adjusted.

Language: Английский

Citations

Population Pharmacokinetics and Dosing Regimen Analysis of Nirmatrelvir in Chinese Patients with COVID-19 Infection DOI

Runcong Zhang,

Jing Fan,

Han Lü

et al.

Drug Design Development and Therapy, Journal Year: 2024, Volume and Issue: Volume 18, P. 5517 - 5527

Published: Dec. 1, 2024

Nirmatrelvir/ritonavir (N/R) is the first drug to receive emergency authorization for treatment of COVID-19 infection. We aimed develop a population pharmacokinetic (PopPK) model evaluate effects potential covariates and explore dosing regimen.

Language: Английский

Citations

Therapeutic Drug Monitoring of Nirmatrelvir/Ritonavir (Paxlovid) in Patients Treated for COVID-19: Results from a Prospective Multicenter Observational Study DOI

Corinna R. Böger,

Jens Martens‐Lobenhoffer, Hans Worthmann

et al.

Therapeutic Drug Monitoring, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 3, 2024

Background: Paxlovid is a combination of the antiviral agents nirmatrelvir and ritonavir indicated for oral treatment high-risk, symptomatic patients with coronavirus disease 2019 (COVID-19). As real-world data on plasma concentrations nirmatrelvir/ritonavir (Paxlovid) are limited, aim this study was to investigate trough levels in clinical setting using therapeutic drug monitoring. Methods: A prospective, noninterventional, multicenter, observational conducted which were simultaneously determined by liquid chromatography tandem mass spectrometry COVID-19. The blood samples collected days 1, 3, 5 after first full-dose day (day 0), patient such as sex, height, weight, renal function, liver enzymes, concomitant (co-) medications obtained describe respect potential influencing factors. Results: total 46 from 21 analyzed. geometric mean C min 4997 ng/mL 529.4 ritonavir. covered wide range, highest being observed advanced age renally excreted comedications. Patients older than 65 years had significantly higher risk achieving excessive above 8840 1440 compared younger (odds ratio 11.2, 95% confidence interval 1.04–120.4). Conclusions: treated COVID-19 reference values 2210 360 stated product characteristics. Advanced eliminated comedication identified possible factors that warrant further investigation.

Language: Английский

Citations

Factors influencing Nirmatrelvir/Ritonavir concentration in patients with COVID-19 DOI

Ping Xu, Lijun Zhang,

Qingguo Wu

et al.

BMC Infectious Diseases, Journal Year: 2024, Volume and Issue: 24(1)

Published: Dec. 18, 2024

Language: Английский

Citations